{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T02:23:14Z","timestamp":1789438994173,"version":"build-2803163510"},"reference-count":37,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1614,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1177\/0091270010370460","type":"journal-article","created":{"date-parts":[[2010,5,22]],"date-time":"2010-05-22T02:08:38Z","timestamp":1274494118000},"page":"512-526","source":"Crossref","is-referenced-by-count":18,"title":["Single- and Multiple-Dose Pharmacokinetics, Safety, and Tolerability of the Selective \u03b17 Neuronal Nicotinic Receptor Agonist, ABT-107, in Healthy Human Volunteers"],"prefix":"10.1002","volume":"51","author":[{"given":"Ahmed A.","family":"Othman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Lenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walid M.","family":"Awni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,3,7]]},"reference":[{"key":"10.1177\/0091270010370460-BIB1|cit1","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003154.pub3","article-title":"Memantine for dementia","author":"Areosa","year":"2005","journal-title":"Cochrane Database of Systematic Reviews (Online)"},{"key":"10.1177\/0091270010370460-BIB2|cit2","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005593","article-title":"Cholinesterase inhibitors for Alzheimer's disease","author":"Birks","year":"2006","journal-title":"Cochrane Database of Systematic Reviews (Online)"},{"key":"10.1177\/0091270010370460-BIB3|cit3","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1016\/S0140-6736(04)16499-4","article-title":"Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial","volume":"363","author":"Courtney","year":"2004","journal-title":"Lancet"},{"key":"10.1177\/0091270010370460-BIB4|cit4","volume-title":"Donepezil, Galantamine, Rivastigmine (Review) and Memantine for the Treatment of Alzheimer's Disease. NICE Technology Appraisal Guidance 111","author":"National Institute for Health and Clinical Excellence (NICE)","year":"2006"},{"key":"10.1177\/0091270010370460-BIB5|cit5","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/S0169-328X(99)00030-3","article-title":"Regional distribution of nicotinic receptor subunit mRNAs in human brain: comparison between Alzheimer and normal brain","volume":"66","author":"Hellstrom-Lindahl","year":"1999","journal-title":"Brain Research"},{"key":"10.1177\/0091270010370460-BIB6|cit6","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0301-0082(99)00045-3","article-title":"Neuronal nicotinic receptors in the human brain","volume":"61","author":"Paterson","year":"2000","journal-title":"Progress in Neurobiology"},{"key":"10.1177\/0091270010370460-BIB7|cit7","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/S0166-2236(96)10073-4","article-title":"Presynaptic nicotinic ACh receptors","volume":"20","author":"Wonnacott","year":"1997","journal-title":"Trends in Neurosciences"},{"key":"10.1177\/0091270010370460-BIB8|cit8","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0014-2999(00)00006-6","article-title":"alpha7 nicotinic acetylcholine receptors and modulation of gabaergic synaptic transmission in the hippocampus","volume":"393","author":"Alkondon","year":"2000","journal-title":"European Journal of Pharmacology"},{"key":"10.1177\/0091270010370460-BIB9|cit9","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1046\/j.0022-3042.2002.00805.x","article-title":"Direct evidence that release-stimulating alpha7* nicotinic cholinergic receptors are localized on human and rat brain glutamatergic axon terminals","volume":"80","author":"Marchi","year":"2002","journal-title":"Journal of Neurochemistry"},{"issue":"suppl 2","key":"10.1177\/0091270010370460-BIB10|cit10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/00002093-199501002-00002","article-title":"Nicotinic receptors and neurodegenerative dementing diseases: basic research and clinical implications","volume":"9","author":"Whitehouse","year":"1995","journal-title":"Alzheimer Disease and Associated Disorders"},{"key":"10.1177\/0091270010370460-BIB11|cit11","doi-asserted-by":"crossref","first-page":"677","DOI":"10.2174\/138161206775474224","article-title":"Targeting the alpha 7 nicotinic acetylcholine receptor to reduce amyloid accumulation in Alzheimer's disease pyramidal neurons","volume":"12","author":"D'Andrea","year":"2006","journal-title":"Current Pharmaceutical Design"},{"key":"10.1177\/0091270010370460-BIB12|cit12","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0169-328X(00)00031-0","article-title":"Quantitative assessment of nicotinic acetylcholine receptor proteins in the cerebral cortex of Alzheimer patients","volume":"76","author":"Burghaus","year":"2000","journal-title":"Brain Research"},{"key":"10.1177\/0091270010370460-BIB13|cit13","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1046\/j.1471-4159.2000.0740237.x","article-title":"Decreased protein levels of nicotinic receptor subunits in the hippocampus and temporal cortex of patients with Alzheimer's disease","volume":"74","author":"Guan","year":"2000","journal-title":"Journal of Neurochemistry"},{"key":"10.1177\/0091270010370460-BIB14|cit14","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1124\/jpet.108.150094","article-title":"Procognitive and neuroprotective activity of a novel alpha7 nicotinic acetylcholine receptor agonist for treatment of neurodegenerative and cognitive disorders","volume":"329","author":"Roncarati","year":"2009","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1177\/0091270010370460-BIB15|cit15","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.pneurobio.2004.09.006","article-title":"Neuronal nicotinic receptors: from structure to pathology","volume":"74","author":"Gotti","year":"2004","journal-title":"Progress in Neurobiology"},{"key":"10.1177\/0091270010370460-BIB16|cit16","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1124\/jpet.106.118976","article-title":"The novel alpha7 nicotinic acetylcholine receptor agonist N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-[2-(methoxy)phenyl]-1-benzofuran-2- carboxamide improves working and recognition memory in rodents","volume":"321","author":"Boess","year":"2007","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1177\/0091270010370460-BIB17|cit17","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/00008877-199911000-00014","article-title":"AR-R17779, and alpha7 nicotinic agonist, improves learning and memory in rats","volume":"10","author":"Levin","year":"1999","journal-title":"Behavioural Pharmacology"},{"key":"10.1177\/0091270010370460-BIB18|cit18","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.neuroscience.2007.05.013","article-title":"The alpha7 nicotinic receptor agonist 4OH-GTS-21 protects axotomized septohippocampal cholinergic neurons in wild type but not amyloid-overexpressing transgenic mice","volume":"148","author":"Ren","year":"2007","journal-title":"Neuroscience"},{"key":"10.1177\/0091270010370460-BIB19|cit19","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/schbul\/22.3.431","article-title":"Nicotinic receptor function in schizophrenia","volume":"22","author":"Leonard","year":"1996","journal-title":"Schizophrenia Bulletin"},{"key":"10.1177\/0091270010370460-BIB20|cit20","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/0006-3223(94)00252-X","article-title":"Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia","volume":"38","author":"Freedman","year":"1995","journal-title":"Biological Psychiatry"},{"key":"10.1177\/0091270010370460-BIB21|cit21","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/S0006-3223(03)00348-2","article-title":"Dementia rating and nicotinic receptor expression in the prefrontal cortex in schizophrenia","volume":"54","author":"Martin-Ruiz","year":"2003","journal-title":"Biological Psychiatry"},{"key":"10.1177\/0091270010370460-BIB22|cit22","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/ajmg.b.20061","article-title":"Comparison of polymorphisms in the alpha7 nicotinic receptor gene and its partial duplication in schizophrenic and control subjects","volume":"123B","author":"Gault","year":"2003","journal-title":"American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics"},{"key":"10.1177\/0091270010370460-BIB23|cit23","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0014-2999(00)00035-2","article-title":"Smoking and schizophrenia: abnormal nicotinic receptor expression","volume":"393","author":"Leonard","year":"2000","journal-title":"European Journal of Pharmacology"},{"key":"10.1177\/0091270010370460-BIB24|cit24","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/(SICI)1096-8628(20000403)96:2<173::AID-AJMG10>3.0.CO;2-U","article-title":"Schizophrenia and smoking: evidence for a common neurobiological basis","volume":"96","author":"Stassen","year":"2000","journal-title":"American Journal of Medical Genetics"},{"key":"10.1177\/0091270010370460-BIB25|cit25","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/sj.npp.1301423","article-title":"The effects of transdermal nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls","volume":"33","author":"Barr","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1177\/0091270010370460-BIB26|cit26","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0893-133X(02)00324-X","article-title":"Effects of cigarette smoking and nicotine nasal spray on psychiatric symptoms and cognition in schizophrenia","volume":"27","author":"Smith","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"10.1177\/0091270010370460-BIB27|cit27","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/sj.npp.1300881","article-title":"Effects of nicotine nasal spray on cognitive function in schizophrenia","volume":"31","author":"Smith","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1177\/0091270010370460-BIB28|cit28","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1001\/archpsyc.63.6.630","article-title":"Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia","volume":"63","author":"Olincy","year":"2006","journal-title":"Archives of General Psychiatry"},{"key":"10.1177\/0091270010370460-BIB29|cit29","doi-asserted-by":"crossref","unstructured":"Malysz J Anderson DJ Gronlien JH et al. In vitro pharmacological characterization of a novel selective alpha 7 neuronal nicotinic acetylcholine receptor agonist ABT-107 October 1721, 2009","DOI":"10.1124\/jpet.110.167072"},{"key":"10.1177\/0091270010370460-BIB30|cit30","unstructured":"Bitner RS Bunnelle WH Buccafusco J et al. The novel alpha-7 nAChR agonist ABT-107 produces preclinical cognitive efficacy and activation of neurochemical and cellular pathways suggestive of symptomatic and disease modifying efficacy in Alzheimer's disease 2009"},{"key":"10.1177\/0091270010370460-BIB31|cit31","unstructured":"Robb HM Stevens KE Kohlhaas KL et al. Characterization of the novel alpha-7 neuronal nicotinic acetylcholine receptor (nAChR) agonist ABT-107 in mouse models of sensory gating 2009"},{"key":"10.1177\/0091270010370460-BIB32|cit32","unstructured":"Paolone G Ji J Williams S et al. Effects of the novel alpha 7 nAChR agonist ABT-107 on prefrontal glutamatergic and cholinergic activity and attentional performance 2009"},{"key":"10.1177\/0091270010370460-BIB33|cit33","unstructured":"Li J Hu M Gubbins EJ et al. Effects of the novel alpha-7 neuronal nicotinic acetylcholine receptor agonist ABT-107 on cell signaling pathways relevant to cognitive and neuroprotective processes 2009"},{"key":"10.1177\/0091270010370460-BIB34|cit34","doi-asserted-by":"crossref","first-page":"4913","DOI":"10.1073\/pnas.83.13.4913","article-title":"Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology","volume":"83","author":"Grundke-Iqbal","year":"1986","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1177\/0091270010370460-BIB35|cit35","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/BF02816111","article-title":"Mechanism of neurofibrillary degeneration in Alzheimer's disease","volume":"9","author":"Iqbal","year":"1994","journal-title":"Molecular Neurobiology"},{"key":"10.1177\/0091270010370460-BIB36|cit36","volume-title":"Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers: Guidance for Industry","author":"US Food and Drug Administration","year":"2005"},{"key":"10.1177\/0091270010370460-BIB37|cit37","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1176\/appi.ajp.2008.07071135","article-title":"Initial phase 2 trial of a nicotinic agonist in schizophrenia","volume":"165","author":"Freedman","year":"2008","journal-title":"American Journal of Psychiatry"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1177%2F0091270010370460","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1177\/0091270010370460","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T12:57:17Z","timestamp":1657803437000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1177\/0091270010370460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,4]]}},"URL":"https:\/\/doi.org\/10.1177\/0091270010370460","relation":{},"ISSN":["0091-2700"],"issn-type":[{"value":"0091-2700","type":"print"}],"subject":[],"published":{"date-parts":[[2011,4]]}}}